These results strongly indicate that KRG-TS is a beneficial herbal substance inhibiting fibrinogen-, and fibronectin-binding to aIIb/b 3 , and clot retraction, and may prevent platelet aIIb/b 3 -mediated thrombotic disease. In addition, we demonstrate that G-Ro is a novel compound with antiplatelet characteristics of KRG-TS.
Introduction
Platelet aggregation is caused by "inside-out signaling" and "outside-in signaling", which is absolutely essential for the formation of a hemostatic plug when normal blood vessels are injured.
However, platelet aggregation can also cause circulatory disorders, such as thrombosis, atherosclerosis, and myocardial infarction [1] .
Various agonists [i.e., collagen, thrombin, adenosine diphosphate (ADP)] induce "inside-out signaling" to bind adhesive proteins (i.e., fibrinogen, fibronectin, vitronectin) to glycoprotein IIb/ IIIa (aIIb/b 3 ) and platelet membrane integrin, then "outside-in signaling" is subsequently processed to cause a series of signal events (i.e., Ca 2þ mobilization, granule secretion, clot retraction)
[2e4]. Through these signaling events, intravascular platelets finally are aggregated at the site of vascular wall injury, which contributes to intensity of the formation of thrombus. Vasodilator-stimulated phosphoprotein (VASP) phosphorylation inhibits VASP affinity for contractile protein filamentous actin, and fibrinogen binding to aIIb/b 3 to inhibit the final common pathway for platelet aggregation [5, 6] . On the contrary, phosphatidylinositol 3-kinase (PI3K)/Akt phosphorylation involves aIIb/b 3 activation [7] . Therefore, the upregulation of VASP phosphorylation and the downregulation of PI3K/Akt phosphorylation are paramount important indexes to understand aIIb/b 3 activation, and are very useful for evaluating the antiplatelet effect of substances or compounds. For instance, a major catechin analogue, (-)-epigallocatechin-3-gallate from green tea, and caffeic acid are known to produce cAMP via adenylate cyclase activation and subsequently phosphorylates VASP (Ser 157 ) to inhibit [Ca 2þ ] i mobilization [8, 9] .
In addition, abciximab, etifibatide, tirofiban, and lamifiban are known as aIIb/b 3 antagonists [10, 11] .
Ginseng, the root of Panax ginseng Meyer, has been used frequently in traditional Oriental medicine, and is known to have various pharmacological activities such as anti-inflammatory action, antioxidation, antitumor, antidiabetes, and antihepatotoxicity effects [12, 13] . It was recently reported that Korean Red Ginseng has an effect on cardiovascular disease, which is characterized with regard to reduction of blood pressure and arterial stiffness by inhibition of Rho kinase [14] , anticoagulation by prolonged prothrombin and activated partial thromboplastin time [15] , endothelium relaxation by nitric oxide-cyclic guanosine monophosphate (cGMP) pathway [16] , and inhibition of hypercholesterolemia-induced platelet aggregation [17] . In our previous report, we demonstrated that total saponin from Korean Red Ginseng (KRG-TS) is a beneficial traditional Oriental medicine in platelet-mediated thrombotic disease via suppression of cyclooxygenase-1 (COX-1) and thromboxane A 2 (TXA 2 ) synthase to inhibit production of thromboxane A 2 [18] . In addition, KRG-TS is involved in increase of cAMP levels and subsequent reduction of [Ca 2þ ] mobilization in thrombin-induced rat platelet aggregation [19] . With regard to the effects of ginsenosides on platelet aggregation, it is well known that ginsenoside Rg3 (G-Rg3) and its chemical derivatives (dihydroxyginsenoside Rg3, ginsenoside Rp1) have antiplatelet effects by regulating the aggregation-inhibiting molecule cAMP, and aggregationstimulating molecules [20, 21] . In this study, we investigated the novel effects of KRG-TS on the phosphorylation of VASP and dephosphorylation of PI3K and Akt affecting on fibrinogen and fibronectin binding to aIIb/b 3 . In addition, we found that ginsenoside Ro (G-Ro), an oleanane type saponin, in KRG-TS has a potent antiplatelet effect.
Materials and methods
KRG-TS was obtained from R&D Headquarter, Korea Ginseng Corporation (Daejeon, Korea). Ginsenoside Ro was purchased from Ambo Institute (Daejon, Korea). Thrombin was purchased from Chrono-Log Corporation (Havertown, PA, USA). A CytoSelect 48-well cell adhesion assay kit (Fibronectin-Coated, Colorimetric Format) was purchased from Cell Biolabs (San Diego, CA, USA). Akinase inhibitor Rp-8-Br-cAMPS, G-kinase inhibitor Rp-8-BrcGMPS, A-kinase activator 8-(4-chlorophenylthio)-cAMP (pCPTcAMP), and G-kinase activator 8-Br-cGMP and 2-acetoxymethyl (Fura 2-AM) were obtained from Sigma Chemical Corporation (St. Louis, MO, USA 
Preparation of washed human platelets
Human platelet-rich plasma (PRP) anticoagulated with acidcitrate-dextrose solution (0.8% citric acid, 2.2% sodium citrate, 2.45% glucose) was obtained from Korean Red Cross Blood Center (Changwon, Korea). The PRP was centrifuged for 10 min at 125 g to remove a few red blood cells, and was centrifuged for 10 min at 1,300 g to obtain the platelet pellets. The platelets were washed two times with washing buffer (138 mM NaCl, 2.7 mM KCl, 12 mM NaHCO 3 , 0.36 mM NaH 2 PO 4 , 5.5 mM glucose, and 1 mM Na 2 EDTA, pH 6.5). The washed platelets were then resuspended in suspension buffer (138 mM NaCl, 2.7 mM KCl, 12 mM NaHCO 3 , 0.36 mM NaH 2 PO 4 , 0.49 mM MgCl 2 , 5.5 mM glucose, 0.25% gelatin, pH 6.9) to a final concentration of 5 Â 10 8 /mL. All of the aforementioned procedures were carried out at 25 C to avoid platelet aggregation from any effect of low temperatures. The Korea National Institute for the Bioethics Policy Public Institutional Review Board (Seoul, Korea) approved these experiments (PIRB12-072).
Measurement of platelet aggregation
Washed human platelets (10 8 /mL) were preincubated for 3 min at 37 C in the presence of 2mM exogenous CaCl 2 with or without substances, then stimulated with thrombin (0.05 U/mL) for 5 min. Aggregation was monitored using an aggregometer (Chrono-Log Corporation, Havertown, PA, USA) at a constant stirring speed of 1,000 rpm. Each aggregation rate was calculated as an increase in light transmission. The suspension buffer was used as the reference (transmission 0). KRG-TS was dissolved in the platelet suspension buffer (pH 6.9). ), and anti-rabbit IgG-HRP were 1:1,000, 1:1,000, 1:1,000, 1:1,000, 1:1,000, 1:1,000, and 1:10,000, respectively. The membranes were visualized using ECL. The blots were analyzed using the Quantity One, version 4.5 (BioRad, Hercules, CA, USA). The reaction was stopped by the addition of 0.5% paraformaldehyde in phosphate buffered saline, and the samples were placed in the dark. Alexa Fluor 488-fibrinogen binding to platelets was determined using flow cytometry (BD Biosciences, San Jose, CA, USA) and fibrinogen binding to aIIb/b 3 was analyzed using cellQuest software (BD Biosciences, San Jose, CA, USA).
Determination of fibronectin adhesion
Adhesion assay was performed with the CytoSelect 48-well cell adhesion assay kit (Cell Biolabs, San Diego, CA, USA). The plates were coated with fibronectin or bovine serum albumin (BSA) as a negative control. Washed human platelets (10 8 /mL) were incubated for 60 min at 37 C in the presence of thrombin (0.05 U/mL) with or without various concentrations of KRG-TS. After five times washing with phosphate buffered saline, cell stain solution was added and the plates were incubated at room temperature for 10 min. After washing five times, extraction solution was added and the plates were incubated for 10 min. Each sample was transferred to a 96-well microtiter plate and measured with Synergy HT Multi-Model Microplate Reader (BioTek Instruments, Winooski, VT, USA) at an optical density of 560 nm.
Assay of platelet-mediated fibrin clot retraction
Human PRP 250 mL were transferred into a polyethylene tube to avoid clot adherence, then were preincubated with or without KRG-TS (150 mg/mL) for 10 min at 37 C, and subsequently stimulated with thrombin (0.05 U/mL) for 5 min at 37 C. Pictures of fibrin clot were taken at 5 min using a digital camera, and its quantification was carried out by measurement of clot area using the Image J Software (version 1.46, National Institutes of Health, Bethesda, MD, USA). Percentage of clot retraction was calculated as follows:
Retraction (%) by thrombin ¼ (basal area e thrombin area) / basal area Â 100.
Determination of cytosolic-free Ca 2þ ([Ca 2þ ] i )
Human PRP was incubated with 5mM Fura 2-AM at 37 C for 60 min. Because Fura 2-AM is light sensitive, the tube containing the PRP was covered with aluminum foil during loading. The Fura 2-loaded washed platelets were prepared using the procedure described previously and platelets (10 ] i values were calculated using the method of Grynkiewicz et al [22] .
Measurement of cAMP
Washed human platelets (10 8 /mL) were preincubated for 3 min at 37 C with or without G-Ro (200 mM) in the presence of 2 mM CaCl 2 , then stimulated with thrombin (0.05 U/mL) for 5 min for platelet aggregation. The aggregation was terminated by the addition of 80% ice-cold ethanol. cAMP was measured with Synergy HT Multi-Model Microplate Reader (BioTek Instruments) using a cAMP EIA kit.
Statistical analyses
The experimental results are expressed as the mean AE standard deviation accompanied by the number of observations. Data were assessed by analysis of variance (ANOVA). If this analysis indicated significant differences among the group means, then each group was compared by the Newman-Keuls method. Statistical analysis was performed according to the SPSS 21.0.0.0 (SPSS Inc., Chicago, IL, USA). A p value < 0.05 was considered to be statistically significant.
Results

Effects of KRG-TS on thrombin-induced human platelet aggregation
The concentration of thrombin-induced maximal human platelet aggregation was w0.05 U/mL (Fig. 1A) . Therefore, thrombin (0.05 U/mL) was used as the human platelet agonist in this study. In intact platelets, the light transmission in response to various concentrations of KRG-TS (25 mg/mL, 50 mg/mL, 100 mg/mL, 150 mg/mL) was 1.3 AE 0.6% (at 25 mg/mL of KRG-TS), 1.3 AE 0.6% (at 50 mg/mL of KRG-TS), 1.3 AE 0.6% (at 100 mg/mL of KRG-TS), and 1.3 AE 0.6% (at 150 mg/mL of KRG-TS), respectively, which were not significantly different from that (1.0 AE 0.0%) in resting platelets without KRG-TS (Fig. 1B) . When washed human platelets (10 8 /mL) were activated with thrombin, the aggregation rate was increased up to 87.8 AE 5.7%. However, various concentrations of KRG-TS (25e 150 mg/mL) significantly reduced thrombin-stimulated platelet aggregation in a dose-dependent manner (Figs. 1B, C), and the halfmaximal inhibitory concentration (IC 50 ) was w45 mg/mL (Fig. 1D ). This IC 50 is low as compared with that (81.1 mg/mL) from rat platelets [19] . In addition, 150 mg/mL of KRG-TS inhibited to 95.9% thrombineinduced human platelet aggregation (87.8 AE 5.7%).
Effects of KRG-TS on VASP phosphorylation
Because 150 mg/mL of KRG-TS (Fig. 1B) (Fig. 2B) , we investigated whether the inhibition of fibrinogen (Figs. 4Aeb, B) , which indicates that cAMP/A-kinase pathway involves inhibition of fibrinogen binding to aIIb/b 3 in thrombin-induced platelet aggregation. KRG-TS (150 mg/mL)-inhibited fibrinogen binding to aIIb/b 3 was elevated by A-kinase inhibitor Rp-8-Br-cAMPS (Figs. 4Aea, B) , and its stimulatory degree was 350% as compared with that (7.7%) by both KRG-TS and thrombin (Table 1) .
Effects of KRG-TS on PI3K/Akt phosphorylation
As apposed to the phosphorylated VASP, PI3K/Akt phosphorylation stimulates aIIb/b 3 activation and fibrinogen binding [25, 26] .
Thus, we investigated the effect of KRG-TS on phosphorylation of PI3K and its downstream molecule Akt. Thrombin potently phosphorylated PI3K (Fig. 5, lane 2) as compared with that (Fig. 5, lane 1) of intact platelets. However, KRG-TS (Fig. 5, lanes 3 and 4) inhibited thrombininduced PI3K phosphorylation. Moreover, PI3K inhibitor wortmannin, negative control, suppressed thrombin-induced PI3K phosphorylation (Fig. 5, lane 5) . Thrombin elevated the phosphorylation of PI3K target molecule Akt (Fig. 6, lane 2) . However, KRG-TS inhibited thrombin-induced Akt phosphorylation (Fig. 6, lanes 3 and 4) .
Effects of KRG-TS on adhesion to fibronectin
Integrin aIIbb 3 also served as a fibronectin receptor on platelets and occupancy of this receptor is essential for platelet adhesion. Therefore, we determined whether KRG-TS interferes with fibronectin binding to aIIbb 3 . As shown in Fig. 7 , thrombin did not adhere platelets to bovine serum albumin (BSA), negative control, but thrombin potently adhered platelets to fibronectin. These mean that thrombin induced fibronectin adhesion to aIIb/b 3 of platelets, but not BSA (Fig. 7A) . KRG-TS (25e150 mg/mL) dose dependently decreased thrombin-induced fibronectin adhesion, and aIIbb 3 inhibitors (eptifibatide and GR 144053) also inhibited thrombininduced fibronectin adhesion. Next, we investigated whether fibronectin inhibition by KRG-TS was resulted from cAMP/A-kinase activation. A-kinase inhibitor Rp-8-Br-cAMPS increased KRG-TSdecreased fibronectin binding to aIIbb 3 (Fig. 7B) . Moreover, A-kinase activator pCPT-cAMP inhibited thrombin-induced fibronectin binding to aIIb/b 3 (Fig. 7B) , which means that cAMP/A-kinase activation is involved in inhibition of fibronectin adhesion.
Effects of KRG-TS on retraction of fibrin clot
Activation of aIIbb 3 (inside-out signaling) by platelet agonists induces fibrinogen binding to aIIbb 3 , and leads to outside-in aIIbb 3 signaling, containing clot retraction, platelet spreading, stable adhesion, granule secretion, protein phosphorylation, platelet signaling. Photographs in Fig. 8A show that thrombin stimulated the formation of fibrin clot, and the retraction of fibrin clot. The degree of retraction was determined from quantitation of fibrin clot area by Image J Software (version 1.46, National Institutes of Health, Bethesda, MD, USA). As shown in Fig. 8B , thrombin potently retracted fibrin clot, and increased to 60% the rate of clot retraction as compared with that without thrombin intact (55 AE 1.3 mm 2 ).
However, KRG-TS suppressed thrombin-retracted fibrin clot, and its inhibitory degree was 82% as compared with that by thrombin (22 AE 1.1 mm 2 ; Fig. 8B ).
Effects of G-Ro on platelet aggregation, [Ca 2þ
] i mobilization, and cAMP production In our previous report [30] , we showed that protopanaxadiol type saponins (G-Ra1, G-Rb1, G-Rb2, G-Rb3, G-Rc, G-Rd, G-Rh2), and protopanaxatriol type saponins (G-Re, G-Rf, G-Rg1, G-Rg2, GRh1) have no antiplatelet effect on thrombin-induced human platelet aggregation. In this study, however, we found that G-Ro, an oleanane type saponin, has a potent antiplatelet effect. When human platelets (10 8 /mL) were stimulated by thrombin (0.05 U/mL), platelet aggregation was potently increased (Table 2) . However, GRo inhibited thrombin-induced platelet aggregation, its inhibitory degree was 52.0% as compared with that by thrombin (86.7 AE 1.5%; Table 2 ). G-Ro increased to 89.1% the production of Ca 2þ -antagonistic cAMP, and decreased to 77.3% the level of aggregatingmolecule [Ca 2þ ] i in thrombin-induced platelet aggregation ( Table 2 ).
Discussion
Of several aggregation inhibiting molecules, cAMP and cGMP are essential for inhibition of platelet aggregation. These cyclic nucleotides generate various biological functions (i.e., VASP phosphorylation, IP 3 [3, 4, 32] . cAMP-elevating agents (i.e., cilostamide, cilostazole, and forskolin) are known to inhibit PI3K-and Akt-phosphorylation in thrombin-induced platelet aggregation [33] . Therefore, KRG-TS that increases cAMP level [19] may be involved in inhibition of PI3K/Akt phosphorylation, and subsequently could participate in suppression of aIIb/b 3 activation. Platelet adhesion is the first step in the hemostatic response and various adhesive proteins such as von Willebrand factor, collagen, and fibronectin can mediate as substrates for platelet adhesion [34] .
Fibronectin adhesion is mediated by both a 5 b 1 and aIIb/b 3 , and subsequently is involved in platelet spreading, plug formation, and a series of events of outside-in signaling [34, 35] . We clearly showed that KRG-TS strongly attenuated fibronectin binding to aIIb/b 3 in a cAMP/A-kinase-dependent manner, as verified that A-kinase inhibitor Rp-8-Br-cAMPS increased KRG-TS-reduced fibronectin binding in thrombin-induced platelet aggregation.
Fibrinogen binding to aIIb/b 3 is involved in fibrin clot retraction, which is an index of thrombus intensification [27] , and is known to be involved in promotion of atheroprogression [36, 37] . If so, inhibition of fibrinogen-, fibronectin-binding and clot retraction is a clear evidence that KRG-TS might protect platelet-mediated thrombotic disease. Platelet aggregation is generated at the site of vascular wall injury, and is involved in the formation of thrombus. During the formation of thrombus, platelets release cell growth proteins such as platelet-derived growth factor (PDGF), and vascular endothelial growth factor (VEGF) in their a-granule [38, 39] . It is well established that PDGF and VEGF induce the proliferation of fibroblast, vascular smooth cells, and epithelial cells, and subsequently enhance the rate of atherosclerosis lesion progression [40e44]. The progression of atherosclerosis is strongly induced by inflammatory cells such as monocyte/macrophage, and neutrophil [45] . Although KRG-TS has antiplatelet effects, if KRG-TS does not inhibit inflammation by leukocytes, the progression of atherosclerosis lesion would be generated at the site of vascular wall injury, and a question regarding antiplatelet effects of KRG-TS might be raised. Byeon (base); b, thrombin (0.05 U/mL); c, thrombin (0.05 U/mL) þ KRG-TS (25 mg/mL); d, thrombin (0.05 U/mL) þ KRG-TS (50 mg/mL); e, thrombin (0.05 U/mL) þ KRG-TS (100 mg/mL); and f, thrombin (0.05 U/mL) þ KRG-TS (150 mg/mL). (B) Effects of KRG-TS on thrombin-induced fibrinogen binding (%). Determination of fibrinogen binding to aIIb/b 3 was carried out as described in the Materials and methods section. The data are expressed as the mean AE standard deviation (n ¼ 4). * p < 0.05 versus the thrombin-stimulated platelets. et al. [46] reported that saponin fraction inhibits lipopolysaccharide (LPS)-induced inflammation, and it is well reviewed that ginsenosides have anti-inflammatory effects by inhibiting the production of various pro-inflammatory mediators [i.e., prostaglandin E 2 , nitric oxide (NO)] [47] . Recently, it was reported that Korean Red Ginseng saponin fraction downregulates LPS-induced proinflammatory mediators (i.e., NO, interleukin-1b) [48] . In addition, Yang et al. [49] clarified that protopanaxadiol saponin fraction inhibits inflammatory actions via suppression of p38-, JNK2-, and TANK [tumor necrosis factor receptor-associated factor (TRAF) family memberassociated nuclear factor-k-B activator]-binding kinase-1-linked pathway and their corresponding transcription factors (i.e., activation transcription factor 2, interferon regulatory transcription factor 3). Considering these previous reports [46e49], it is thought that KRG-TS may have antithrombotic, and antiatherosclerotic effects without generation of inflammation and progression of atherosclerotic lesion at the site of vascular wall injury. Therefore, KRG-TS is highlighted as a nontoxic antiplatelet compound, and could be clinically applied to the prevention of platelet-mediated thrombosis. This is supported from reports that Korean Red Ginseng has protective effects on rat carotid artery thrombosis in vivo [50] , and both ginseng and ginsenoside are beneficial candidates for prevention of cardiovascular disease [51] . 2) Long-term (4e5 years) intake of red ginseng products (i.e., water extract, tea, drink) is known to inhibit platelet aggregation, blood coagulation, and hyperlipidemia such as indexes of thrombotic diseases and atherosclerosis, and their effects were also well sustained in the patients who have obesity, hyperlipidemia, and hypertension [52, 53] .
Hwang et al. [17] reported that dietary water-extract of Korean Red Ginseng (KRG-WE) inhibited collagen-induced rabbit platelet aggregation under hypercholesterolemia causing atherosclerosis such as cardiovascular disease, and KRG-WE had a strong antiplatelet effects as compared with those caused by lovastatin, an anticholesterolemic drug. Oral administration (250e500 mg/kgbody weight-rat) of KRG-WE significantly inhibited agonists (i.e., ADP, collagen)-induced platelet aggregation, and KRG-WE (300 mg/ mL, 500 mg/mL) inhibited agonists (i.e., ADP, collagen, etc.)-induced washed rabbit platelet aggregation in vitro [49] . If these are physiological concentrations (300 mg/mL, 500 mg/mL) of KRG-WE to inhibit rat and rabbit platelet aggregation in in vitro and in vivo, because it is thought that we used KRG-TS (150 mg/mL) is low concentration as compared with that of KRG-WE in vitro (300 mg/ mL, 500 mg/mL), in this study, it is unknown whether in vitro KRG-TS (150 mg/mL)-mediated antiplatelet effects are also expressed in vivo. These should be studied in the future.
With regard to the G-Ro, Sanada et al. [54] reported that G-Ro is contained in Panax ginseng, Choi [55] reviewed that G-Ro (0.045 w/ w %), and G-Rg3 (20S, 0.006 w/w %) and G-Rg3 (20R, 0.014 w/w %) are contained in Panax ginseng, but not in Panax notoginseng (Sanchi ginseng), and Panax quinquefolius (American ginseng). It is known that G-Ro (1mM) inhibited arachidonic acid-induced platelet aggregation and fibrin formation in vitro [56] , and G-Ro (10e50 mg/kg body weight-rat) administration activated fibrinolysis, indicating the inhibition of fibrin thrombi [57] . Accordingly, when antiplatelet-mediated 200mM (about 191.4 mg/kg) of G-Ro (MW. 957.1) is administered to animals, it is unknown whether thrombininduced platelet aggregation would also be inhibited in vivo. However, considering thrombin is involved in platelet aggregation and fibrin formation, it is thought that G-Ro 200mM (191.4 mg/kg) would be involved in inhibition of platelet aggregation and fibrin formation. Currently, G-Ro is known to have anti-inflammatory effects [58] . If so, it is thought that G-Ro may also have a protective effect on thrombosis through inhibition of platelet aggregation and inflammation.
It is known that G-Ro does not inhibit collagen-induced [Ca 2þ ] i mobilization [59] , however, in this study, we confirmed that G-Ro inhibits [Ca 2þ ] i mobilization by increasing Ca 2þ -antagonistic cAMP in thrombin-induced platelet aggregation. Therefore, it is thought that G-Ro-elevated cAMP also may be involved in VASP (Ser  157 ) phosphorylation in the same manner that KRG-TS activated cAMPdependent VASP (Ser 157 ) phosphorylation.
G-Rg3 (20S, 20R) is known to have antiplatelet effects by regulating various aggregating molecules [20, 21] . Recently, we also reported that only G-Rg3 (20S, 20R) of protopanaxadiol saponin have inhibitory effects on thrombin-induced platelet aggregation [30] . Antiplatelet effects of G-Ro and G-Rg3 indicated that Panax ginseng would have an excellent antithrombotic effect by inhibiting platelet aggregation than that by any ginsengs, and G-Ro and G-Rg3 (20S, 20R) are major compounds in KRG-TS only of Panax ginseng. Western blotting was performed as described in the Materials and methods section. The data are expressed as the mean AE standard deviation (n ¼ 4). * p < 0.05 versus the thrombin-stimulated platelets. In conclusion, the most important result of this study is that KRG-TS significantly inhibits binding of adhesive proteins (i.e., fibrinogen, fibronectin) to aIIb/b 3 by activating the phosphorylation of VASP (Ser 157 ) and dephosphorylation of PI3K and Akt, which contribute to inhibition of thrombotic formation. Therefore, we suggest that KRG-TS may be a physiologically effective negative regulator in thrombosis, atherosclerosis, and myocardial infarction via inhibition of platelet aggregation.
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